MEDICAMEN ORGANICS Stock Price Today (NSE: MEDIORG)

MEDICAMEN ORGANICS

21.102.95 (12.27%)
Market Closed

Fundamental Score

...

MEDICAMEN ORGANICS Share Price — Live NSE/BSE Price, Fundamentals & Analysis

MEDICAMEN ORGANICS share price today is 21.10, down 12.27% on NSE/BSE as of 19 June 2026. MEDICAMEN ORGANICS (MEDIORG) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 32.06 (Cr). The 52-week high for MEDIORG share price is 49.70 and the 52-week low is 19.50. At a P/E ratio of 7.00x, MEDIORG is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 17.85% and a debt-to-equity ratio of 0.48.

MEDICAMEN ORGANICS Share Price Chart — NSE/BSE Historical Performance

No data
High
29.25
Low
21.10
Volume
4.6K
Change
-17.78%

MEDICAMEN ORGANICS share price chart: -17.78% return over the past month. 52-week high ₹49.70, 52-week low ₹19.50.

MEDICAMEN ORGANICS — Last 10 Trading Days

DateOpenHighLowCloseVolume
20.0521.8019.5021.1050.00K (Cr)
24.0024.0524.0024.054.00K (Cr)
25.6027.0025.6027.004.00K (Cr)
26.0026.0026.0026.002.00K (Cr)
27.0029.2026.7529.0014.00K (Cr)
29.2029.2029.2029.202.00K (Cr)
29.2029.2029.2029.204.00K (Cr)
29.2529.2529.2529.252.00K (Cr)
29.2029.2029.2029.206.00K (Cr)
23.2523.2523.2523.258.00K (Cr)

MEDICAMEN ORGANICS — Last 12 Months Price History

MonthOpenHighLowCloseChange
20.0521.8019.5021.10+5.24%
29.2029.2024.0024.05-17.64%
23.2529.2523.2529.25+25.81%
23.0023.0020.5521.10-8.26%
26.6030.2525.1025.30-4.89%
26.4526.6522.0026.65+0.76%
28.4028.4023.5024.60-13.38%
33.4533.4527.2027.55-17.64%
33.2538.0033.2537.90+13.98%
36.4537.0031.4031.70-13.03%
43.5043.5034.0036.45-16.21%
43.3045.0036.1544.75+3.35%

Returns & Performance

Good

Return on Equity (ROE)

17.85%

Profit generated per ₹1 of shareholder equity

Good

Return on Capital (ROCE)

16.88%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

MEDICAMEN ORGANICS Valuation Check

Excellent

Price to Earnings (P/E)

7.00x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.77x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

59.73%

% shares held by company founders/management

Poor

FII Holding

0.07%

% shares held by foreign institutional investors

Poor

DII Holding

3.69%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

35.10%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

7.47%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Average

Debt to Equity Ratio

0.48x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

10.65x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

N/A

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

MEDICAMEN ORGANICS Fundamental Analysis & Valuation Benchmarking

Educational evaluation of MEDIORG across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Strong Return on Equity (17.85%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (16.88%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Attractive Valuation (P/E: 7.00 vs Industry: 31.77)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (35.10%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Interest Coverage (10.65x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (59.73%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

2 factors identified

Limited Institutional Interest (FII+DII: 3.76%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

MEDICAMEN ORGANICS vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare MEDICAMEN ORGANICS with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
42/100
21
₹32.06
7.0
Average
17.85%
Good
16.88%
Good
0.5
Excellent
0.00%
65.2/100
1844
₹433738.68
37.6
Average
16.86%
Good
20.21%
Excellent
0.1
Excellent
23.78%
Excellent
9.87%
Good
0.89%
67.9/100
6798
₹170445.88
68.6
Average
15.35%
Good
20.44%
Excellent
0.0
Excellent
10.41%
Good
11.65%
Good
0.47%
65.3/100
4538
₹126430.62
58.4
Average
26.52%
Excellent
27.05%
Excellent
0.3
Excellent
13.84%
Good
7.72%
Good
0.86%
Cipla Ltd...
CIPLA500087
59/100
1418
₹123059.76
22.6
Average
17.77%
Good
22.72%
Excellent
0.0
Excellent
28.68%
Excellent
9.97%
Good
0.85%
59.2/100
1319
₹105224.96
18.2
Average
17.96%
Good
22.69%
Excellent
0.2
Excellent
22.28%
Excellent
13.26%
Good
0.63%
Lupin Ltd...
LUPIN500257
66.7/100
2276
₹95148.15
22.0
Average
20.62%
Excellent
21.30%
Excellent
0.3
Excellent
54.88%
Excellent
8.11%
Good
0.58%
68.7/100
957
₹94253.78
18.7
Average
21.21%
Excellent
24.31%
Excellent
0.4
Excellent
25.92%
Excellent
10.27%
Good
1.17%
50.6/100
2420
₹92012.53
52.6
Average
14.68%
Average
15.98%
Good
0.6
Good
11.73%
Good
15.79%
Excellent
0.04%
28.8/100
1436
₹70798.69
20.7
Average
11.08%
Average
14.18%
Average
0.2
Excellent
3.87%
Average
6.55%
Good
0.33%
59.5/100
5452
₹67075.29
28.5
Average
19.39%
Good
20.38%
Excellent
0.2
Excellent
13.93%
Good
9.21%
Good
0.80%

MEDICAMEN ORGANICS Quarterly Performance

Latest quarterly metrics for MEDIORG — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

7.47%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

35.10%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

MEDICAMEN ORGANICS Technical Indicators

SMA 50, SMA 200, RSI and volume signals for MEDIORG — calculated from daily price history

43RSI 14
Neutral — RSI 43

Momentum is balanced — neither overbought nor oversold.

SMA 50
26
▼ Price below SMA 50 — Short-term bearish
SMA 200
33
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
11K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

MEDICAMEN ORGANICS Financial Statements

Annual income statement, balance sheet and cash flow for MEDICAMEN ORGANICS (MEDIORG) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for MEDICAMEN ORGANICS

About MEDIORG (MEDICAMEN ORGANICS)

MEDICAMEN ORGANICS (MEDIORG) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a curr...ent market capitalisation of ₹32.06 (Cr). MEDICAMEN ORGANICS has delivered a Return on Equity (ROE) of 17.85% and a ROCE of 16.88%. The debt-to-equity ratio stands at 0.48, reflecting the company's capital structure. Investors tracking MEDIORG share price can monitor key metrics including P/E ratio, promoter holding of 59.73%, and quarterly earnings growth.

Company Details

Symbol:MEDIORG
Industry:Pharmaceuticals
Sector:Pharmaceuticals
Website:N/A

MEDIORG Share Price: Frequently Asked Questions

What is the current share price of MEDICAMEN ORGANICS?

MEDICAMEN ORGANICS (MEDIORG) trades at ₹21.10 on NSE. Market cap ₹32.06 (Cr). Educational data only.

What is the P/E ratio of MEDICAMEN ORGANICS?

MEDICAMEN ORGANICS has a P/E of 7.00x vs industry average 31.77x.

What is the Bull Run score for MEDICAMEN ORGANICS?

MEDICAMEN ORGANICS has a Bull Run score of 42/100 based on 25+ financial parameters.

Does MEDICAMEN ORGANICS pay dividends?

MEDICAMEN ORGANICS has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of MEDICAMEN ORGANICS?

MEDICAMEN ORGANICS has ROE of 17.85%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of MEDICAMEN ORGANICS?

MEDICAMEN ORGANICS has debt-to-equity of 0.48.

Is MEDICAMEN ORGANICS a good investment?

Bull Run gives MEDICAMEN ORGANICS a score of 42/100. This is not investment advice — consult a SEBI-registered advisor.